Search | Clinical Trials Finder

The live registry is temporarily unavailable. These stored records may be incomplete or out of date. Check the official record for current status and contact information.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 5:01 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 745–768 of 5,282 matching trials from the local directory fallback.

Filters: Boston, Massachusetts Clear all

Conditions: Gastroesophageal Junction Adenocarcinoma, HER2-positive Gastric Cancer
Interventions: 5-fluorouracil, Capecitabine, Cisplatin, Oxaliplatin, Pembrolizumab, Rilvegostomig, Trastuzumab, Trastuzumab deruxtecan; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 840 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 58
States / cities: Anchorage, Alaska • Phoenix, Arizona • Duarte, California + 51 more

Conditions: Treatment Resistant Depression
Interventions: Active-stimulation, Sham-stimulation; Device
Lead sponsor: Abbott Medical Devices; Industry
Eligibility: 22 Years to 70 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 26
States / cities: Birmingham, Alabama • Los Angeles, California • Sacramento, California + 19 more

Conditions: Cardiovascular Diseases, Hypertension, Vascular Diseases
Interventions: Paradise Ultrasound Renal Denervation Treatment; Device
Lead sponsor: ReCor Medical, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2031
U.S. locations: 46
States / cities: Long Beach, California • Los Angeles, California • Sacramento, California + 39 more

Conditions: Proliferative Vitreoretinopathy, Rhegmatogenous Retinal Detachment
Interventions: Netarsudil Ophthalmic; Drug
Lead sponsor: Massachusetts Eye and Ear Infirmary; Other
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Dietary Habits
Interventions: Day shift protocol - Diet order A-B, Day shift protocol - Diet order B-A, Night shift protocol - Diet order A-B, Night shift protocol - Diet order B-A; Behavioral
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years to 45 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Peripheral Vascular Diseases
Interventions: Any eligible commercially available Boston Scientific Corporation (BSC) drug-eluting device.; Device
Lead sponsor: Boston Scientific Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 5,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2028
U.S. locations: 53
States / cities: Jonesboro, Arkansas • Los Angeles, California • Sacramento, California + 42 more

Conditions: Anatomic Stage IV Breast Cancer AJCC v8, Hormone Receptor Positive Breast Carcinoma, Metastatic Breast Carcinoma, Prognostic Stage IV Breast Cancer AJCC v8
Interventions: Abemaciclib, Questionnaire Administration; Drug · Other
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 70 Years and older
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 6
States / cities: Duarte, California • Irvine, California • Long Beach, California + 3 more

Conditions: Emphysema
Interventions: Spiration Valve System (SVS); Device
Lead sponsor: Olympus Corporation of the Americas; Industry
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2029
U.S. locations: 16
States / cities: Phoenix, Arizona • Mountain View, California • Coral Gables, Florida + 11 more

Conditions: Dermatomyositis, Juvenile Dermatomyositis, Juvenile Polymyositis, Myositis, Polymyositis
Interventions: Not listed
Lead sponsor: National Institute of Environmental Health Sciences (NIEHS); NIH
Eligibility: 2 Years to 100 Years
Enrollment: 580 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2011
U.S. locations: 8
States / cities: Miami, Florida • Baltimore, Maryland • Bethesda, Maryland + 5 more

Conditions: Hidradenitis Suppurativa (HS)
Interventions: Soquelitinib; Drug
Lead sponsor: Corvus Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 11
States / cities: West Lafayette, Indiana • Bowling Green, Kentucky • Owensboro, Kentucky + 8 more

Conditions: Schizophrenia
Interventions: ML-007C-MA; Drug
Lead sponsor: MapLight Therapeutics; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 45
States / cities: Little Rock, Arkansas • Rogers, Arkansas • Bellflower, California + 39 more

Conditions: Pancreatic Adenocarcinoma Metastatic
Interventions: Nab-paclitaxel + Gemcitabine, OMTX705, Tislelizumab (i.v. 200mg); Drug
Lead sponsor: Oncomatryx Biopharma S.L.; Industry
Eligibility: 18 Years and older
Enrollment: 69 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Heart Failure (Pediatric), Left Ventricular Systolic Dysfunction
Interventions: Finerenone (Kerendia, BAY94-8862), Placebo; Drug
Lead sponsor: Bayer; Industry
Eligibility: 6 Months to 17 Years
Enrollment: 111 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 22
States / cities: Aurora, Colorado • Wilmington, Delaware • Gainesville, Florida + 18 more

Conditions: Small Cell Lung Cancer (SCLC)
Interventions: Durvalumab 50 MG/ML; Drug
Lead sponsor: Alliance Foundation Trials, LLC.; Other
Eligibility: 18 Years and older
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 6
States / cities: Chicago, Illinois • Scarborough, Maine • Boston, Massachusetts + 2 more

Conditions: Carotid Artery Calcification, Carotid Artery Diseases
Interventions: Carotid Intravascular Lithotripsy (IVL); Device
Lead sponsor: Shockwave Medical, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 185 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2032
U.S. locations: 25
States / cities: Little Rock, Arkansas • Rancho Mirage, California • Sacramento, California + 20 more

Conditions: Prostate Cancer
Interventions: AAA817, ARPI, Standard of Care; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 100 Years · Male only
Enrollment: 940 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2032
U.S. locations: 42
States / cities: Homewood, Alabama • Tucson, Arizona • Orange, California + 37 more

Conditions: ASCVD, ASCVD Management, Vascular Inflammation
Interventions: CANAKINUMAB (ILARIS®), Saline (NaCl 0,9 %) (placebo); Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: COVID-19 SARS-CoV-2 Infection
Interventions: ibuzatrelvir, placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 12 Years and older
Enrollment: 2,330 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 90
States / cities: Huntsville, Alabama • Little Rock, Arkansas • Bakersfield, California + 66 more

Conditions: Diabetic Peripheral Neuropathic Pain
Interventions: Placebo (matched to Pregabalin), Placebo (matched to SUZ), Pregabalin, Suzetrigine; Drug
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 1,100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 76
States / cities: Anniston, Alabama • Birmingham, Alabama • Daphne, Alabama + 68 more

Conditions: Gram-negative Bacterial Infection
Interventions: Part A: ATM-AVI Single Dose, Cohorts 1-4, Part B: Multiple-dose ATM-AVI, Cohorts 1-4; Drug
Lead sponsor: Pfizer; Industry
Eligibility: Up to 39 Weeks
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 11
States / cities: Orange, California • Aurora, Colorado • Indianapolis, Indiana + 4 more

Conditions: Long COVID, ME/CFS, PASC
Interventions: Low-Dose Naltrexone, Placebo, Pyridostigmine; Drug · Other
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years to 70 Years
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Endometrial Cancer, Recurrent Endometrial Cancer, TP53
Interventions: Abemaciclib, Letrozole, Pembrolizumab; Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 8
States / cities: Aurora, Colorado • Boston, Massachusetts • Foxborough, Massachusetts + 3 more

Conditions: Biliary Tract Cancer, Breast Cancer, Cervical Cancer, Cholangiocarcinoma, Colon Cancer, Endometrial Cancer, Esophageal Cancer, Gallbladder Cancer, Gastric Cancer, GastroEsophageal Cancer, Head and Neck Cancer, Hepatocellular Cancer, Mesothelioma, Non-small Cell Lung Cancer, Ovarian Cancer, Pancreatic Cancer, Prostate Cancer, Rectal Cancer, Renal Cancer, Thyroid Cancer, Urothelial Carcinoma (UC)
Interventions: MDX2001; Drug
Lead sponsor: ModeX Therapeutics, An OPKO Health Company; Industry
Eligibility: 18 Years and older
Enrollment: 330 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 6
States / cities: Denver, Colorado • Miami, Florida • Boston, Massachusetts + 3 more

Conditions: ACL Tear, Osteoarthritis, Knee, Post-traumatic Osteoarthritis
Interventions: Metformin, Placebo; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years to 45 Years
Enrollment: 512 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2030
U.S. locations: 9
States / cities: Atlanta, Georgia • Iowa City, Iowa • Lexington, Kentucky + 6 more

Search by objective public record fields.

A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer

Treatment ResistAnt Depression Subcallosal CingulatE Network DBS (TRANSCEND)

Global Paradise System US Post Approval Study

Topical Netarsudil for the Prevention of Proliferative Vitreoretinopathy in Patients With Retinal Detachment

Can Food Timing Reduce Your Diabetes Risk?

Drug-Eluting Registry: Real-World Treatment of Lesions in the Peripheral Vasculature

Abemaciclib and Endocrine Therapy in Older Patients With Breast Cancer.

STRIVE Post-Market Registry Study

Environmental Risk Factors for the Anti-synthetase Syndrome

Safety and Efficacy of Soquelitinib in Adults With Hidradenitis Suppurativa

A Long-Term Open-Label Study of ML-007C-MA in Adults With Schizophrenia

Clinical Trial of OMTX705 in Combination With Gemcitabine/Nab-Paclitaxel and Tislelizumab in Patients With Advanced/Metastatic Pancreatic Adenocarcinoma

A Study to Learn More About How Well Finerenone Works, How Safe it is, and How it Moves Into, Through, and Out of the Body Compared to Placebo When Taken With Standard Treatment in Children With Heart Failure and Left Ventricular Systolic Dysfunction

Adjuvant Chemotherapy and Immunotherapy for Completely Resected Small Cell Lung Cancer

Study of the Shockwave Medical SkyRunner Carotid Intravascular Lithotripsy (IVL) System for the Treatment of Calcified Carotid Arteries Prior to Trans-Carotid Stenting (SKYWARD Trans-Carotid IDE [Investigational Device Exemption] Study)

Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC

Effects of IL-1 Beta Inhibition on Vascular Inflammation in TET2 Clonal Hematopoiesis

A Study to Learn About a Study Medicine Called Ibuzatrelvir in Adult and Adolescent Patients With COVID-19 Who Are Not Hospitalized But Are at Risk For Severe Disease

Evaluation of Efficacy and Safety of Suzetrigine for Pain Associated With Diabetic Peripheral Neuropathy

A Study to Learn About the Study Medicine Aztreonam-Avibactam (ATM-AVI) in Infants and Newborns Admitted in Hospitals With Bacterial Infection (CHERISH)

LIFT: Life Improvement Trial

ALPINE: Maintenance Letrozole/Abemaciclib

Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors

Preventing Injured Knees From osteoArthritis: Severity Outcomes